The Pricing Shell Game: Understanding AWP vs. WAC in Pharmacy Benefits

While it is easy to dismiss these terms as industry jargon, the specific benchmark used in a contract determines how much “invisible” profit a PBM can rake in. When a broker moves a client from an AWP-based contract to a more transparent model, they are essentially pulling back the curtain on traditional PBM’s profit centers.

The Pricing Hierarchy

Understanding the relationship between these numbers is essential for identifying where money is being leaked from a health plan:

• WAC (Wholesale Acquisition Cost): Think of this as the manufacturer’s “List Price.” It is the most stable benchmark, as it is published directly by the drug maker and does not include discounts or rebates.
• AWP (Average Wholesale Price): This is mathematically derived from WAC (usually AWP = WAC x 1.2). Because it is an inflated “suggested” price rather than a true market cost, it is easily manipulated.
• MAC (Maximum Allowable Cost): This is a PBM-generated list that sets the upper limit they will pay for a generic drug. PBMs often keep these lists private, which allows them to pay the pharmacy a low MAC price but charge the employer a high AWP-based price.

NADAC (National Average Drug Acquisition Cost): This is a newer, federal benchmark that reflects the actual price pharmacies pay to purchase drugs. It is often the most transparent metric available.

Where the Brokenness Occurs

The primary issue isn’t the existence of these benchmarks, but how they are leveraged to create “Spread Pricing.” In a broken system, intermediaries use the delta between these numbers to pad their own bottom line:

• The Mark-up Trap: The 20% gap between WAC and AWP is often where the PBM hides its margin. If a contract is based on AWP, the PBM has a 20% cushion to play with before they even begin applying “discounts.”
• The Generic Spread: On generic drugs, the gap between AWP and the actual cost to the pharmacy is massive. A PBM might offer an “80% discount off AWP” on a generic drug that actually costs 95% less than AWP, pocketing the 15% difference.
• Hidden Inflation: When manufacturers raise the WAC, the AWP automatically follows. In an AWP-discount model, the employer’s costs rise instantly, even if the PBM’s “discount” percentage stays the same.
• Rebate Retention: Because AWP is used to set the stage for rebates, PBMs may favor a high-AWP drug over a lower-cost alternative simply because the high sticker price generates a larger rebate, much of which the PBM may keep.

The SHARx Solution: Cutting Through the Acronyms

SHARx helps brokers and employers bypass the AWP/WAC shell game entirely by moving away from legacy pricing benchmarks that favor the intermediary. Our solution is designed to strip away the “black box” of pharmaceutical procurement and replace it with a model focused on the actual net cost of the medication.

By unbundling high-cost claims from the traditional PBM cycle, SHARx ensures that plan sponsors aren’t just getting a “discount” off an inflated price. They are getting the best possible price.

With SHARx, employers can provide a clear path out of the pricing maze through:

• Transparent Procurement: Eliminate the reliance on inflated AWP benchmarks, focusing instead on direct, advocacy-based sourcing that targets the lowest net cost.
• Fiduciary Alignment: Our interests are aligned with the plan sponsor. We don’t profit from the spread between pricing benchmarks, ensuring every cent of expense optimization stays with the client.
• Professional Advocacy: We provide the clinical and financial oversight necessary to verify that medications are priced fairly and that members are supported throughout the process.

By shifting the conversation from “discounts” to “actual costs,” SHARx empowers brokers to deliver a pharmacy benefit that is both financially sustainable and fundamentally transparent.